An Open-label Dose Finding Study Followed by a Parallel Group, Randomized, Double-blind Study to Evaluate the Safety, Tolerability and Pharmacodynamics of 12 Week BGS649 Treatment in Obese, Hypogonadotropic Hypogonadal Men.
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2017
At a glance
- Drugs BGS 649 (Primary)
- Indications Hypogonadism
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis
- 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society.
- 22 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 May 2012 Planned End Date changed from 1 Apr 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History